Clinical Course and Outcomes of COVID-19 Infection in Patients Treated with Rituximab: A Tertiary Care Center Experience.

Thamer Saad Alhowaish Moustafa S Alhamadh Alaa MathkourMarwan AlamoudiHossam Ali AlqahtaniAbdulrahman Alrashid

Published in: Open access rheumatology : research and reviews (2023)

Treatment with RTX seems to be a potential risk factor for unfavorable outcomes in COVID-19 patients. RTX should be used with caution or avoided unless the benefit clearly outweighs the risk.

Keyphrases

tertiary care
sars cov
diffuse large b cell lymphoma
risk assessment
combination therapy
insulin resistance
hodgkin lymphoma
glycemic control
replacement therapy